#Cambridge #Skin Health #AI-powered testing #Sequential

Sequential Secures $3.5 Million for AI-Driven Discovery in Skin Health

In an impressive move towards revolutionizing skin health research, Sequential, a frontrunner in genomic testing from non-invasive human samples, has acquired $3.5 million in its first equity funding round. The investment is led by Sparkfood and Corundum Systems Biology (CSB), with participation from notable entities including Dermazone Holdings, SOSV, and Scrum Ventures. This sum complements an earlier funding achievement, bringing Sequential's total investment to $7.5 million, encompassing both dilutive and non-dilutive sources.

Innovative Testing Solutions

Sequential's expertise lies in harnessing its proprietary non-invasive testing platform to digitize and analyze how various ingredients in cosmetic and pharmaceutical products affect both microbial and host biomarkers. This translates complex biological information into clear, actionable insights. They pride themselves on possessing one of the industry's most extensive clinical datasets, featuring over 50,000 samples and 4,000 tested ingredients across a global participant pool exceeding 10,000 individuals.

The newly obtained funding aims to accelerate the development of an AI-enhanced discovery engine grounded in Sequential’s unparalleled clinical dataset. This will facilitate the identification, optimization, and discovery of next-generation active complexes and innovative bioactive ingredients tailored for skincare products.

Oliver Worsley, PhD, and CEO of Sequential, stated, "Our mission focuses on bringing pharmaceutical-grade evidence and computational precision to personal care. By leveraging AI on one of the world’s largest dermatological health datasets, we aim to unveil new skin biomarkers and advance past incremental product improvements to systematically engineer and validate transformative ingredient combinations. This capital infusion empowers us to realize that ambition."

A Vision for the Future of Personal Care

Commenting on the investment, Anouk Veber, Business Unit Leader at Sparkfood, said, "Sequential bridges biology, clinical validation, and consumer product development, linking molecular and microbial biomarkers to tangible product performance. We are confident that their AI-driven platform stands to redefine how next-gen personal care products are imagined and marketed. This investment also aligns nicely with Sparkfood's vision for innovative collaboration across the personal care sector."

Echoing this sentiment, Hidehiko Otake, CEO of Corundum Systems Biology, expressed that Sequential’s goals resonate with their own commitment to enhancing human health through the power of large data sets and advanced technology, emphasizing the shared resolve to redefine personal care’s future.

By integrating systems biology research, comprehensive clinical research frameworks, and sophisticated computational modeling, Sequential aims to establish a new benchmark for data-informed innovation in personal care and related health categories. The company is positioned to expand its biomarker discovery initiatives domestically and globally, as it builds a scalable engine for unlock the next generation of scientifically validated compounds.

About Sequential

Founded through the collaboration of PhD experts, Sequential stands as a leader in skin microbiome research. The firm, which operates from its labs in Cambridge, New York City, and Singapore, has garnered support from esteemed organizations like Innovate UK and Enterprise Singapore. The company's efforts have been recognized with accolades such as the title for the